GLP1ID-HFD-A
GLP-1 ID Individualized Dosing
Individualized Weight Loss
GLP-1 ID Individualized Dosing
*Based on Ivim’s published study, Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks. Not a head-to-head study. RX required after clinical evaluation. This is a compounded medication and is not FDA-approved. Compounded drugs have not undergone FDA review for safety, efficacy, or quality. See Ivím website for full safety information. Results may vary.
Your Ivím GLP-1 ID Patient Journey
Here’s what to expect:
What your individual program includes
Competitors
Medicine
ONLY
$850 value
coaching & community
$500 value
formulated supplements
Ivím Health App
What to Expect
Your Ivím GLP-1 ID Patient Journey
Check In
Weekly check-ins track symptoms and progress.
Custom Adjustments
Doctor-approved changes based on your feedback.
Feel the Difference
Goals: Less side effects. More progress.
Founded for Better Care
Founded for Better Care
Ivím Health was founded in 2021 by Dr. Taylor Kantor, alongside his brother Anthony and Anthony’s wife, Kelly, to reimagine care for cardiometabolic conditions—making it more accessible, individualized, and data-driven.
Blending medical precision with a holistic mindset, they set out to build a modern model of care that puts the individual first.
Understanding individualized compounded GLP-1 medications
GLP-1 ID combines customized care, flexible medication options, and ongoing support to deliver better results than one-size-fits-all approaches.
Yes, when prescribed by a licensed provider and monitored appropriately.
The most common side effects of compounded semaglutide and compounded tirzepatide are similar to their brand-name counterparts and are typically gastrointestinal in nature, including:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Bloating or gas
- Decreased appetite or early satiety
These side effects are usually mild to moderate and tend to improve over time, especially with gradual dose escalation under provider supervision.
You still have full access to Zepbound® and Wegovy® if you choose through our traditional GLP-1 program.
Our intake questionnaire and consultation with a provider determine if you medically qualify.
Our GLP-1 ID programs are structured based on the duration you select at checkout. Most patients begin with the Jumpstart option, which is a 4-month commitment.
You can choose from 1, 2, 4, or 6-month programs, and your access to care, medication, and support will remain active for the full duration you select.
Because GLP-1 medications are prescribed and shipped based on your selected program length, cancellation is not available once your program has started.
(All compounded medication purchases are considered part of the GLP-1 ID program.)
*Based on Ivim’s published study, Ivim patients following the Ivim Protocol lost an average of 46% more weight over 68 weeks when compared to another published clinical GLP-1 trial that included a daily 500-calorie deficit, 150 minutes of weekly exercise, and in-person counseling every four weeks. Not a head-to-head study. RX required after clinical evaluation. This is a compounded medication and is not FDA-approved. Compounded drugs have not undergone FDA review for safety, efficacy, or quality. See Ivím website for full safety information. Results may vary.
Individualized virtual integrative medicine (IVIM): A clinical model for enhanced GLP-1 therapeutic outcomes
